脊髓灰质炎加上内分泌疗法将早期乳腺癌复发率削减28%,但在新西兰,获得治疗的机会面临资金拖延。 Ribociclib plus endocrine therapy cuts early-stage breast cancer recurrence by 28%, but access in New Zealand faces funding delays.

在2025年ESMO大会上提出的一项全球研究表明,已经在新西兰用于晚期乳腺癌的 ribociclib,在早期,激素受体阳性,HER2-阴性乳腺癌中,与内分泌治疗相结合时,可降低复发风险28%,无论淋巴结状况如何,都能获得好处. A global study presented at the 2025 ESMO Congress shows that ribociclib, already used in New Zealand for advanced breast cancer, reduces recurrence risk by 28% in early-stage, hormone receptor-positive, HER2-negative breast cancer when combined with endocrine therapy, with benefits seen regardless of lymph node status. 这种治疗每年可以防止数百起转移性病例,但新西兰药房正在对治疗进行审查,以便更广泛地使用,尽管2025年有限的资金威胁到及时获得治疗的机会。 The treatment, which could prevent hundreds of metastatic cases annually, is under review by New Zealand’s Pharmac for broader use, though limited 2025 funding threatens timely access. 倡导者敦促更快地批准扩大救生治疗,特别是针对毛利人和太平洋岛屿妇女等高风险群体的救生治疗,因为澳大利亚和联合王国也有类似的获得治疗的机会。 Advocates urge faster approval to expand life-saving treatment, especially for high-risk groups like Māori and Pacific women, as similar access exists in Australia and the UK.